Clinical Research Directory
Browse clinical research sites, groups, and studies.
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Sponsor: USWM CT, LLC
Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
Official title: Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Key Details
Gender
All
Age Range
10 Years - Any
Study Type
INTERVENTIONAL
Enrollment
103
Start Date
2019-12-31
Completion Date
2026-07-31
Last Updated
2026-02-25
Healthy Volunteers
No
Conditions
Interventions
Letetresgene autoleucel (lete-cel, GSK3377794)
letetresgene autoleucel will be administered.
Fludarabine
Fludarabine will be used as the lymphodepleting chemotherapy
Cyclophosphamide
Cyclophosphamide will be used as the lymphodepleting chemotherapy.
Locations (38)
City of Hope National Medical Center
Duarte, California, United States
Stanford Hospital and Clinics
Stanford, California, United States
Sarah Cannon Research Institute
Denver, Colorado, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
University of Chicago
Chicago, Illinois, United States
University of Iowa College of Medicine
Iowa City, Iowa, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan Medical Center
Ann Arbor, Michigan, United States
Minnesota Oncology Hematology
Minneapolis, Minnesota, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Washington University
St Louis, Missouri, United States
Memorial Sloan Kettering cancer center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Ohio State University-Columbus
Columbus, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Pittsburgh, Hillman Cancer Centre
Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
University Of Texas Southwestern Medical Center
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Virginia Commonwealth University
Richmond, Virginia, United States
Fred Hutchinson Cancer Research
Seattle, Washington, United States
Froedtert Hospital
Milwaukee, Wisconsin, United States
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
CIUSSS de L'Est-De-Lile-De-Montreal
Montreal, Quebec, Canada
Centre Léon Bérard
Lyon, France
CHU de Bordeaux GH Sud Hôpital Haut Lévêque
Pessac, France
Fondazione IRCCS Instituto Nazionale Dei Tumori
Milan, Lombardy, Italy
Ircss Istituto Clinico Humanitas
Rozzano (MI), Lombardy, Italy
The Netherlands Cancer Institute
Amsterdam, Netherlands
Hospital Santa Creu Y Sant Pau
Barcelona, Spain
Ico Duran y Reynals l'Hospitalet de Llobrega
Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Virgen Del Rocio
Seville, Spain
Royal Marsden Hospital
London, United Kingdom
University College Hospital-London
London, United Kingdom
Christie Hospital NHS Foundation Trust
Manchester, United Kingdom